Becker's Healthcare January 26, 2022
While the FDA has greenlit the use of COVID-19 antiviral pills made by Merck and Pfizer, there are differences in the authorizations for each. The supplies of both remain limited.
Eleven notes:
Pfizer’s Paxlovid
1. The FDA issued an emergency use authorization for Pfizer’s antiviral pill regimen, Paxlovid, Dec. 22, making it the first available at-home COVID-19 treatment.
2. The treatment is administered as three tablets (two tablets of nirametrelvir and one tablet of ritonavir) taken twice daily for no more than five consecutive days.
3. The authorization for Paxlovid is broader than Merck’s molnupiravir. Paxlovid is authorized for use in patients 12 and older who weigh at least 88 pounds and are at high risk...
Today's Sponsors
Today's Sponsor